stockrowDaVita Inc.
DVA Healthcare Medical Care Facilities
DaVita Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 billion, up 6.46% from fiscal 2024.
- Revenue
- +4.62%
- EPS
- +67.0%
- Free cash flow
- −45.8%
- Total debt
- +5.07%
Quarter to September 2026, against a year earlier
Follow DVA
Alert me
DaVita Inc. (DVA) EPS (diluted)
DaVita Inc.'s EPS (diluted) for fiscal 2025 was $9.84, down 8.29% from $10.73 in fiscal 2024. Over the twelve months to 30 September 2026 it was $13.58. Over the past ten years it has ranged from $0.92 (fiscal 2018) to $10.73 (fiscal 2024); the current reading is higher than 91% of that period. DaVita Inc. ranks 6th of 48 Medical Care Facilities companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $9.84 | (8.29%) |
| FY2024 | $10.73 | 44.61% |
| FY2023 | $7.42 | 26.84% |
| FY2022 | $5.85 | (34.27%) |
| FY2021 | $8.90 | 41.05% |
| FY2020 | $6.31 | 19.73% |
| FY2019 | $5.27 | 472.83% |
| FY2018 | $0.92 | (73.49%) |
| FY2017 | $3.47 | (19.11%) |
| FY2016 | $4.29 | 243.20% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $3.40 | (15.42%) |
| Jun 2026 | $4.02 | 40.07% |
| Mar 2026 | $2.87 | (12.77%) |
| Dec 2025 | $3.29 | 61.27% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| THC Tenet Healthcare Corporation compare | $37.19 |
| UHS Universal Health Services, Inc. compare | $23.99 |
| CHE Chemed Corporation compare | $20.90 |
| DVA DaVita Inc. | $13.58 |
| ENSG The Ensign Group, Inc. compare | $6.72 |
| EHC Encompass Health Corporation compare | $6.40 |
| FMS Fresenius Medical Care AG & Co. KGaA compare | $1.87 |
| PACS PACS Group, Inc. compare | $1.77 |
| CON Concentra Group Holdings Parent, Inc. compare | $1.69 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on DVA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement